GMP News, GMP guidelines, GMP Violations, GMP warnings A Public Health Global News Portal

Welcome to FDA, WHO, EU, TGA, CDSCO guidelines...and GMP Violations news/warning letters..

150000+ Industry Leaders already read it everyday

Monday, August 29, 2016

European Competent Authorities publish GMP Non-Compliance Statements In total 35 non GMP observations

Image result for ema logo
Nature of non-compliance : In total 35 observations were made by the inspection team over the course of the inspection. Five of them were categorised as major deficiencies and therefore potentially leading to a risk to the human and veterinary patient when using active pharmaceutical ingredients manufactured at the inspected site. - The installation and execution of an Enterprise Resource Planning System, hosting GMP relevant data but outside of the quality management system, demonstrated a lack of QA oversight. - Repackaging operations were conducted without any documentation and QA approval. - The issuance of labels for raw materials and APIs was found inadequately controlled. - Within the instrumental laboratory the Company violated basic principles on data integrity, i.e. manual integration without justification and QA oversight. - The Company’s approach on the validation of computerised systems (Shimadzu LabSolutions) was considered as not in compliance with the requirements.

Action taken/proposed by the NCA :
Recall of batches already released
No immediate recall is needed. Each involved NCA should evaluate, following assessment conducted in conjunction with MAHs, if a potential recall of medicinal product is needed. The risk based evaluation should take in account if there are alternative suppliers and potential risk of shortage. Given the nature of non-compliances, assessment should include a complete retest of all imported batches of active substance.
Prohibition of supply
Due to the nature of non-compliances, prohibition of supply is recommended.
Suspension or voiding of CEP (action to be taken by EDQM)
This inspection was carried out as part of the EDQM inspection Programm. The impact of this NCS on the CEPs is to be decided by the EDQM. The concerned CEPs are Simvastatin Butylated Hydroxy Anisole 50 - 150 ppm R1-CEP 2006-091-Rev 00; Simvastatin Butylated hydroxy anisole 0.18-0.22% R1-CEP 2007-155-Rev 01; Simvastatin Antioxidant Butylated Hydroxy Toluene 0.01% R1-CEP 2003-257-Rev 03

This supplier should not be approved in any new/ongoing applications. Each involved NCA should evaluate if the supplier should be removed from existing MAs.

An additional comment points out that the manufacturer also produces an antibiotic for the French market. This API was not within the scope of the inspection...

the Spanish authority has also published two GMP Non-Compliance Statements: one for a Chinese API manufacturer, the other one for a Spanish medicinal products manufacturer.

The CEP of the Chinese company (JINAN JINDA PHARMACEUTICAL CHEMI. CO LTD in Shandong) was withdrawn in 2015 already. It turned out the CAPA measures promised after the inspection hadn't been implemented satisfyingly. In total, the Spanish authority identified 2 critical and 8 major deficiencies, whereby the critical deviations concerned the safety and control of raw data as well as OOS assessments. Among other things, the main deficiencies concerned process and cleaning validation.
Regarding the Spanish manufacturer of liquids (ALCOR, S.L. in Guadalajara), the lack of resources, facilities, personnel and materials has been particularly criticised. The CAPA proposed were considered not appropriate by the authority who sees the accumulation of tasks and responsibilities in some personnel as a risk to quality.

Last but not least, the British Authority (MHRA) also wrote a GMP Non-Compliance Statement. Here, an Indian manufacturing site of Hospira Healthcare that manufactures sterile medicinal products (lyophilisates, small-volume liquids and aseptically filled powders) was concerned. For the MHRA, the conclusion to the many deficiencies discovered  there (e.g. inappropriate room segregation and classification, deviating media fills without any root cause finding,  etc.) can be reduced to one causal point: a lack of scientific knowledge.

Source: EMA, gmp compliance



Post a Comment

Related Posts Plugin for WordPress, Blogger...


Popular Posts


Subscribe Free GMP Guidelines

Enter your email address:

Delivered by FeedBurner



Subscribe via email for free


Enter your email address:

Delivered by FeedBurner

Contact Form


Email *

Message *

Menu :
Powered by Blogger.



    Related Posts Plugin for WordPress, Blogger...


    2016 (37) 2017 (85) 2018 (9) 211 CFR (1) 211.63 (1) 483 (5) AAFA (1) Abbott (2) AboutUs (1) ALCOA (1) Alerts (2) ANDA (1) Anshu (2) Antibiotics (1) apic (1) APR17 (8) APS (2) Articles (4) AstraZeneca (1) Aug17 (2) Aurobindo (2) Author (2) Authors (8) Biocon (1) cadila (1) capa (3) CDSCO (5) Change control (1) Christian Green (1) cipla (2) Cleaning validation (1) Data Integrity (9) dec16 (15) Definations (1) Deviations (1) Donald Trump’s (2) Downloads (17) Dr.Reddy's (4) eca (1) EIR (1) Eli Lilly (1) ema (12) EU (9) FDA (70) FDA Guide (18) FEB17 (15) Genaral (1) General Health (2) GMP (1) GMP News (36) gsk (2) GuidelineEU (10) GuidelinesG (5) GuidelineW (2) GV/0117/001 (1) GVAuthors (3) Health (4) HOSPIRA (1) ICH (3) ICHGuide (3) import alert (1) India (1) ISPE (1) James Bullock (1) JAN17 (23) Jul17 (8) July17 (1) Jun17 (4) Lupin (2) Mahender (39) MAR17 (13) Mar18 (7) May17 (10) MHRA (3) MHRA guide (1) Mumbai (1) Mylan (4) Natco (1) News (55) Non Complinaces (1) Nov16 (5) Novartis (1) oct (1) Oct16 (10) OCT17 (1) PDA (1) Personnel (1) pfizer (1) pics (8) Picsguide (2) QbD (1) Quality Docs (1) RCA (1) Recall (1) safety (1) Sanjeev Kumar Singh (4) Sanofi (1) Sep16 (6) Siegfried Schmitt (2) SUN (1) TGA (3) TOP 10 PHARMA (1) USP (2) Validation (3) Warning Letters (43) WHO (6) zika (1)


    Theme Support